## Abstract We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopaโinduced dyskinesias in Parkinson's disease (PD) in an openโlabel pilot study. Nine PD patients who were experiencing peakโdose dyskinesias for at least 25% of the awake day and wer
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease
โ Scribed by P. Stathis; S. Konitsiotis; G. Tagaris; D. Peterson; on Behalf of VALID-PD Study Group
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 265 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Our objective was to develop parameters for objective ambulatory measurements of levodopa-induced dyskinesias (LID) in patients with Parkinson's disease (PD). Twentythree PD patients with mild to severe LID were submitted to a standardized protocol of 1-minute recordings during rest, talking, stress
## Abstract In a placeboโcontrolled, singleโblinded, crossover study, we assessed the effect of โrealโ repetitive transcranial magnetic stimulation (rTMS) versus โshamโ rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD). Ten patients with PD and prominent dyskinesias
Symptomatic respiratory disturbance as a consequence of levodopa (L-dopa) therapy for Parkinson's disease (PD) has been described only rarely and may be underrecognized in clinical practice. We report on two patients with PD in whom the introduction or augmentation of L-dopa therapy was associated w
## Abstract Involuntary upward and lateral eye movements are described in two Parkinson's disease patients who also experience levodopaโinduced chreoathetoid limb movements simultaneously. These brief deviations of gaze represent a rare ocular manifestation of dyskinesia and are similar to oculogyr